Abstract: The present invention provides methods and devices for the delivery of gene therapy pharmaceuticals to a mammalian organ in situ, in vivo, ex vivo, or in vitro. In particular, the methods and devices relate to contacting a mammalian organ viral vector with a gene therapy pharmaceutical in a re-circulating, oxygenated perfusate solution for a sufficient time to provide an effective delivery of the gene therapy pharmaceutical to the target tissue.

Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.

Abstract: A method for the effective delivery of viral vector gene therapy pharmaceuticals in a recirculating, oxygenated perfusate solution, to a target tissue comprising contacting the target tissues with a viral vector gene therapy pharmaceutical in a recirculating, oxygenated perfusate solution, where said solution is held about 37° C., such that there is effective delivery of the viral vector gene therapy pharmaceutical.

Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular Congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.

Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular Congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.

Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.

Abstract: The present invention is directed to processes for isolating and identifying the nucleotide sequence of a gene for a novel macrophage receptor with collagenous structure, termed "MARCO". The new macrophage receptor with a collagenous domain binds gram positive and negative bacteria and acetylated LDL. Moreover, the invention relates to the nucleotide sequence for MARCO identified by the process of the invention and the isolated and purified polypeptide chain encoded by such a sequence.

Abstract: The instant invention provides for apparatus and methods for the efficient administration of pharmaceuticals to target cells, tissues and/or organs, for a variety of functional uses.

Abstract: The present invention is directed to processes for isolating and identifying the nucleotide sequence of a gene for a novel macrophage receptor with collagenous structure, termed "MARCO". The new macrophage receptor with a collagenous domain binds gram positive and negative bacteria and acetylated LDL. Moreover, the invention relates to the nucleotide sequence for MARCO identified by the process of the invention and the isolated and purified polypeptide chain encoded by such a sequence.

Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.

Abstract: The present invention provides for a method for preparing antibodies that specifically detect the type IV collagen .alpha.5 chain that is defective in various basement membrane disorders such as in X chromosome-linked Alport's syndrome. The invention further provides for the use of such antibodies to detect the .alpha.5(IV) collagen chain in solutions and other human tissue specimens using immunological methods comprised of antibodies specific for said protein. Along this line, the invention relates to the use of the specific antibodies to examine the presence or absence of the .alpha.5(IV) collagen chain in the tissues, e.g. skin or kidneys, etc. of patients with renal failure, possibly due to Alport's syndrome. In addition, a further object of the present invention is to provide compositions, comprising both labeled and unlabeled peptides containing sequences from the .alpha.

Abstract: The present invention provides for a method for preparing antibodies that specifically detect the type IV collagen .alpha.5 chain that is defective in various basement membrane disorders such as in X chromosome-linked Alport's syndrome. The invention further provides for the use of such antibodies to detect the .alpha.5(IV) collagen chain in solutions and other human tissue specimens using immunological methods comprised of antibodies specific for said protein. Along this line, the invention relates to the use of the specific antibodies to examine the presence or absence of the .alpha.5(IV) collagen chain in the tissues, e.g. skin or kidneys, etc. of patients with renal failure, possibly due to Alport's syndrome.

Abstract: The present invention provides for a method for isolating and partially characterizing the nucleotide sequence for a novel polypeptide chain of human basement membrane (type IV) collagen, referred to as the .alpha.5(IV) polypeptide chain. The invention provides for the use of the identified nucleotide sequence (or DNA fragments thereof) to detect mutations in individual genes specific for the .alpha.5(IV) chain which can, directly or indirectly, produce several human diseases. Moreover, the invention also relates to procedures for determining genetic or acquired disorders of basement membranes using the identified nucleotide sequence (or DNA fragments thereof) of the .alpha.5(IV) polypeptide chain, probes specific to DNA fragments of said nucleotide sequence,or antibodies to the nucleotide sequence or DNA parts thereof.

Abstract: Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.

Abstract: Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.

Abstract: Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.